---
title: A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion
nct_id: NCT01210027
overall_status: COMPLETED
sponsor: University of Michigan Rogel Cancer Center
study_type: OBSERVATIONAL
primary_condition: Liver Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01210027.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01210027"
ct_last_update_post_date: 2024-12-05
last_seen_at: "2026-05-12T06:16:48.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion

**Official Title:** A Pilot Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion

**NCT ID:** [NCT01210027](https://clinicaltrials.gov/study/NCT01210027)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 143
- **Lead Sponsor:** University of Michigan Rogel Cancer Center
- **Conditions:** Liver Cancer
- **Start Date:** 2007-03
- **Completion Date:** 2023-04-01
- **CT.gov Last Update:** 2024-12-05

## Brief Summary

Researchers at the the University of Michigan are conducting a research project to assess how a course of radiation therapy changes the way blood flows through the liver. To be able to do this, the researchers will be using MRI (magnetic resonance imaging) scans completed before, during, and after radiation therapy. MRI's will be done on 4 or 5 occasions. On each occasion, you will be injected with a fluid called gadolinium (a contrast agent) before getting an MRI. This contrast agent makes it easier for the Researchers to see your organs in the scans, and causes any abnormal areas to become very bright on the MRI. This agent will be injected into a vein in your arm or leg. Each MRI scan will last approximately 45 minutes.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients must be ≥18 years of age.
* The patient's planned cancer management is radiation to the liver with or without chemotherapy.
* Patients must have a performance status of 0-2 and a life expectancy of at least 3 months.
* Patients should have no contraindications to having a contrast enhanced MRI scan.

Exclusion Criteria:

* Women who are pregnant or breastfeeding are excluded.
* Prisoners are excluded
```

## Primary Outcomes

- **Measure of Liver Function Before, During and After Radiation** _(time frame: 2-3 months for treatment; indefinite for follow-up)_ — The primary objective of this research is to assess how a course of radiation therapy changes the way blood flows through the liver. Researchers want to use the information collected from this research for future research, to see if this change in blood flow indicates that an individual patient is at higher risk for complications from the radiation therapy, specifically Radiation-Induced Liver Disease (RILD). To be able to do this, the researchers will be using MRI (magnetic resonance imaging) scans completed before, during, and after radiation therapy.

## Secondary Outcomes

- **Measure of Liver Perfusion** _(time frame: Follow-up - Approximately 7 Years)_
- **Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes** _(time frame: Follow-up - Approximately 7 years)_

## Locations (1)

- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of michigan rogel cancer center|ann arbor|michigan|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01210027.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01210027*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*